In this article, we will list the 5 Penny Stocks with Potential to Rise 1000 Percent. Please visit 10 Penny Stocks with Potential to Rise 1000 Percent if you’d like to see an extended list and our methodology behind it.
5. Rezolve AI PLC (NASDAQ:RZLV)
Rezolve AI PLC (NASDAQ:RZLV) is one of the penny stocks with potential to rise 1000 percent.
Rezolve AI said on February 10 that it had agreed to acquire Reward Loyalty UK Limited in an all-cash deal valued at $230 million, with the purchase funded from existing resources. The company described the transaction as non-dilutive, meaning it does not require the issuance of new equity, and said the acquisition is expected to add about $90 million of EBITDA-accretive revenue.
The deal gives Rezolve a profitable commerce media, engagement, and loyalty platform that already operates across banking and retail channels. In its announcement, the company said Reward has live enterprise deployments spanning banks, retailers, and payment ecosystems, which Rezolve expects will broaden the reach of its RezolvePay and Brain Commerce offerings across tens of millions of cardholders and a large merchant network.
Rezolve framed the acquisition as a scale move rather than a distant bet. The company said Reward’s platform has delivered more than $2.5 billion in cashback to consumers, generated more than $1 billion in gross merchandise value in 2025, and worked with banks including NatWest, Monzo, Mashreq, and Zand.
Rezolve AI PLC (NASDAQ:RZLV) is an AI-driven commerce and payments infrastructure company focused on digital retail tools, including Brain Commerce for product discovery and Brain Checkout for one-tap checkout.
4. agilon health, inc. (NYSE:AGL)
agilon health inc. (NYSE:AGL) is one of the penny stocks with potential to rise 1000 percent.
agilon health said on March 18, 2026, that it would implement a 1-for-25 reverse stock split of its common stock as it works to regain compliance with the New York Stock Exchange’s minimum bid price requirement. The company said the reverse split is expected to become effective on March 30, 2026, at around 5:01 p.m. Eastern Time, with shares expected to begin trading on a split-adjusted basis on March 31 under the existing ticker symbol AGL.
The company said stockholders had approved an amendment at a March 17 special meeting authorizing a reverse split in a range of 1-for-5 to 1-for-25, with the board given discretion to determine the final ratio. Following that meeting, the board approved the 1-for-25 ratio. agilon said the move is intended not only to lift its share price above $1.00 for continued NYSE listing compliance, but also to potentially improve the marketability and liquidity of the stock and broaden investor interest.
Under the reverse split, every 25 outstanding shares will be combined into one share, leaving about 16.6 million shares outstanding immediately after the effective time. The company said no fractional shares will be issued, with stockholders instead receiving cash in lieu of any fractional interests. It also said equity awards and other outstanding equity-linked securities would be adjusted proportionally.
agilon health, inc. (NYSE:AGL) partners with physician groups and health systems to support a value-based care model for senior patients, providing technology, capital, and operational support across its network.
3. Aardvark Therapeutics, Inc. (NASDAQ:AARD)
Aardvark Therapeutics Inc. (NASDAQ:AARD) is one of the penny stocks with potential to rise 1000 percent.
Aardvark Therapeutics said on March 23, 2026, that it had voluntarily paused its Phase 3 HERO and open-label extension trials of ARD-101 in Prader-Willi syndrome, as well as the ARD-201 obesity program, while it works with the FDA on next steps. The company said it expects to provide further guidance on both programs in the second quarter of 2026.
The update was driven by cardiac findings from a separate healthy volunteer study, not from prior Prader-Willi syndrome trials. Aardvark said two of eight participants in a healthy volunteer cohort dosed at 1,600 mg twice daily without prior dose escalation had QRS increases greater than 25% from baseline, while another had an increase below that threshold. In a follow-on healthy volunteer cohort dosed at 800 mg twice daily for up to one week, one of 23 participants had a transient QRS increase of less than 25% from baseline, and another had an increase greater than 25%. The company said these observations were reversible, were not reported as serious adverse events, and were not accompanied by serious cardiac symptoms.
Aardvark said preliminary analysis showed a clear exposure-response relationship, with higher plasma concentrations associated with a higher risk of QRS prolongation. It added that ARD-101 data were published in Molecular Metabolism in March. The company ended 2025 with $110.0 million in cash, cash equivalents, and short-term investments, which it said should fund operations into the second quarter of 2027.
Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapies designed to suppress hunger in Prader-Willi syndrome and metabolic diseases.
2. Allogene therapeutics (NASDAQ:ALLO)
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the penny stocks with potential to rise 1000 percent.
Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in the pivotal Phase 2 ALPHA3 trial in first-line consolidation for large B-cell lymphoma. The company said the study is the first designed to test whether early, measurable residual disease-guided consolidation with cema-cel can prevent recurrence in LBCL, and that it is enrolling across more than 60 activated clinical trial sites in academic and community cancer centers, including sites outside the United States. An interim futility analysis is planned for April 2026 and will compare MRD clearance rates and early safety outcomes between the cema-cel arm and observation.
The company also highlighted progress in autoimmune disease with ALLO-329, a dual CD19/CD70 AlloCAR T candidate that uses its Dagger technology to reduce or potentially eliminate conventional lymphodepletion. Allogene said the Phase 1 RESOLUTION basket trial is enrolling in dose escalation across indications, including systemic lupus erythematosus, lupus nephritis, scleroderma, and inflammatory myositis, with initial data from the first dosing cohort expected in June 2026.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company developing off-the-shelf allogeneic CAR T cell products for cancer and autoimmune disease.
1. Humacyte Inc. (NASDAQ:HUMA)
Humacyte, Inc. (NASDAQ:HUMA) is one of the penny stocks with potential to rise 1000 percent.
On March 27, 2026, BTIG maintained its Buy rating on Humacyte but cut its price target to $3 from $6 after the company reported fourth-quarter and full-year 2025 results earlier the same day. Humacyte reported $0.5 million in fourth-quarter revenue and $2.0 million in full-year revenue, while BTIG said the quarterly figure missed its $1.3 million estimate. The analyst note also said the company posted a loss per share of $0.13, versus consensus expectations for a $0.12 loss.
BTIG said the trauma launch for Symvess remains choppy on a quarter-to-quarter basis. The firm noted that Humacyte sold about 25 units in the fourth quarter, down from about 29 in the third quarter of 2025, while the price per unit declined to roughly $17,000 from about $24,500. BTIG also flagged elevated operating expenses and said cash remains a critical focus.
Even so, BTIG pointed to some commercial progress, with the number of hospitals ordering Symvess for trauma use rising to 27 from 16. Humacyte also said on March 27 that it received a purchase commitment for a minimum of $1.475 million for a clinical evaluation and outreach program in Saudi Arabia, while both the company and BTIG highlighted interim top-line results from the Phase 3 V012 study in dialysis access expected in the second quarter of 2026. BTIG said the dialysis access market represents a larger opportunity than the trauma market.
Humacyte, Inc. (NASDAQ:HUMA) is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale.
While we acknowledge the potential of HUMA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HUMA and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
